Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Systemic Immunosuppressant — Bullous Diseases / Autoimmune Dermatoses

Mycophenolate Mofetil

Brand names: CellCept, Myfenax

Mycophenolate mofetil is an immunosuppressant used after transplantation and as a steroid-sparing agent in various autoimmune and inflammatory conditions.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

ADULTS DOSAGE Kidney Transplant 1 g twice daily, orally ( 2.2 ) Heart Transplant 1.5 g twice daily orally ( 2.3 ) Liver Transplant 1.5 g twice daily orally ( 2.4 ) PEDIATRICS Kidney Transplant 600 mg/m 2 orally twice daily, up to maximum of 2 g daily ( 2.2 ) Heart Transplant 600 mg/m 2 orally twice daily, (starting dose) up to a maximum of 900 mg/m 2 twice daily (3 g) ( 2.3 ) Liver Transplant 600 mg/m 2 orally twice daily,daily (starting dose) up to a maximum of 900 mg/m 2 twice daily (3 g) ( 2.4 ) Reduce or interrupt dosing in the event of neutropenia. ( 2.5 ) See full prescribing information (FPI) for: adjustments for renal impairment and neutropenia ( 2.5 ) 2.1 Important Administration …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2026-05-14. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Clinical monograph

How it works

It inhibits inosine monophosphate dehydrogenase, selectively suppressing T- and B-lymphocyte proliferation.

Prescribing in practice

  • It is highly teratogenic and causes miscarriage — strict pregnancy prevention is required for anyone able to become pregnant, with relevant advice for men too (MHRA).
  • Bone-marrow suppression and increased infection risk (including reactivation and, rarely, PML) occur; gastrointestinal effects are common.
  • Avoid live vaccines; absorption is reduced by some antacids and by sevelamer.

Monitoring

Monitor full blood count regularly (especially early), review for infection, and confirm pregnancy-prevention measures.

Counselling the patient

  • Use effective contraception and avoid pregnancy — it can seriously harm a baby.
  • Report sore throat, fever, bruising or other signs of infection.
  • Take it consistently and attend monitoring blood tests.

Evidence & guidelines

Used after transplantation and as a steroid-sparing immunosuppressant, with strict pregnancy-prevention requirements (MHRA).

Reference: EMA Pregnancy Prevention Programme; BAD Pemphigus Guidelines; BAD Bullous Pemphigoid Guidelines 2012 (updated); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways